Cystadrops
(Cysteamine)PreclinicalSmall molecule
Cystadrops is one of 47 small molecule programs targeting Efficacy. It is currently in Preclinical.
1
Indications
11
Total Trials
2
Active Trials
46
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
145 competitors in Efficacy
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Tivicay
GSKPhase 3
Rogaine
PfizerPhase 3
Rayos
RRoxane Laboratories
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Alimta
SShawn Eagle
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Insulin 320
Novo NordiskPhase 3
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
QL2107
Qilu Pharmaceutical Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cystinosis3 trials
Cystic Fibrosis2 trials
Effectiveness1 trial
Treatment1 trial
3 more indications
Pneumonia1 trial
Efficacy1 trial
Efficacy of Topical Cysteamine in Nephropathic Cyctinosis
Completed·TThe Eye Center and The Eye Foundation for Research in Ophthalmology·N/A·NCT02766855·26 enrolled
Efficacy and Safety1 trial
Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation
Unknown status·—·N/A·NCT05206318·40 enrolled
Regulatory
FDA Approval Timeline[4]
Oct 2, 2012
CYSTARAN
NDA NDA200740
Aug 19, 2020
CYSTADROPS
NDA NDA211302
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cysteamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLeadiant Biosciences, Inc.